meganuclease

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – French firm Cellectis and North Carolina-based Precision Biosciences have filed two new suits against each other alleging infringement of US patents covering modified meganucleases.

Helix will promote Cellectis' Genome Positioning System line of products and services in India.

The French firm gains access to Cyto Pulse's electroporation technologies and equipment.

Cedarlane will distribute Cellectis Bioresearch's kits in Canada.

The patent has been the subject of ongoing litigation between the French and US biotech firms.

The agricultural products company will use Cellectis' meganuclease tools and will invest in the French firm.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.